Non-animal methodologies within biomedical research and toxicity testing
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Laboratory animal models are limited by scientific constraints on human applicability, and increasing regulatory restrictions, driven by social concerns. Reliance on laboratory animals also incurs marked - and in some cases, prohibitive - logistical challenges, within high-throughput chemical testing programmes, such as those currently underway within Europe and the US. However, a range of non-animal methodologies is available within biomedical research and toxicity testing. These include: mechanisms to enhance the sharing and assessment of existing data prior to conducting further studies, and physicochemical evaluation and computerised modelling, including the use of structure-activity relationships and expert systems. Minimally-sentient animals from lower phylogenetic orders or early developmental vertebral stages may be used, as well as microorganisms and higher plants. A variety of tissue cultures, including immortalised cell lines, embryonic and adult stem cells, and organotypic cultures, are also available. In vitro assays utilising bacterial, yeast, protozoal, mammalian or human cell cultures exist for a wide range of toxic and other endpoints. These may be static or perfused, and may be used individually, or combined within test batteries. Human hepatocyte cultures and metabolic activation systems offer potential assessment of metabolite activity and organ-organ interaction. Microarray technology may allow genetic expression profiling, increasing the speed of toxin detection, well prior to more invasive endpoints. Enhanced human clinical trials utilising micro- dosing, staggered dosing, and more representative study populations and durations, as well as surrogate human tissues, advanced imaging modalities and human epidemiological, sociological and psycho- logical studies, may increase our understanding of illness aetiology and pathogenesis, and facilitate the development of safe and effective pharmacologic interventions. Particularly when human tissues are used, non-animal models may generate faster, cheaper results, more reliably predictive for humans, whilst yielding greater insights into human biochemical processes. Greater commitment to their development and implementation is necessary, however, to efficiently meet the needs of high-throughput chemical testing programmes, important emerging testing needs, and the ongoing development of human clinical interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Transforming Environmental Health Protection
Collins, F. S., Gray, G. M., & Bucher, J. R. (2008) · Science · doi:10.1126/science.1154619 · Cited by 630
Estimates for worldwide laboratory animal use in 2005
Taylor, K., Gordon, N., Langley, G., & Higgins, W. (2008) · Alternatives to Laboratory Animals · doi:10.1177/026119290803600310 · Cited by 210
Medical progress depends on animal models - doesn't it?
Matthews, R. A. (2008) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.2007.070164 · Cited by 132
Challenges and opportunities with modelling and simulation in drug discovery and drug development
Lavé, T., Parrott, N., Grimm, H. P., Fleury, A., & Reddy, M. (2007) · Xenobiotica · doi:10.1080/00498250701534885 · Cited by 115 · cited 1×
“The benefits of modelling and simulation during drug design and pre-clinical assessment can potentially be realised through integration of any available data on physicochemical properties, PK and PD (Balls, 1994; lavé et al., 2007; Wishart, 2007).”
BackgroundSystematic reviews of animal experiments demonstrate poor human clinical and toxicological utility
Knight, A. (2007) · Alternatives to Laboratory Animals · doi:10.1177/026119290703500610 · Cited by 105 · cited 1×
“Results in animal models were frequently equivocal, or inconsistent with human outcomes (Knight, 2007).”
ResultSelf-citation
Cited by
Wetmore, B. A., Wambaugh, J. F., Ferguson, S. S., Sochaski, M. A., Rotroff, D. M., Freeman, K., Clewell, H. J., Dix, D. J., Andersen, M. E., Houck, K. A., et al. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfr254 · Cited by 415
Paglialunga, S., Morimoto, B. H., Clark, M., & Friedrichs, G. S. (2019) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2019.106596 · Cited by 26
Drug-mediated toxicity: illuminating the ‘bad’ in the test tube by means of cellular assays?
Tralau, T., & Luch, A. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.03.015 · Cited by 24
Metadata
- Venue
- ALTEX
- Publisher
- ALTEX Edition
- Published
- 2008
- Volume
- 25
- Issue
- 3
- Pages
- 213-31
- ISSN
- 0946-7785 (ISSN-L)
- 1868-596X
- OpenAlex
- W1585581989
- Cited by
- 51
- References
- 6
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.